Abstract
The use of hormonal drugs for contraception and menopausal replacement therapy is widespread throughout the world. However, the use of these drugs is associated with an increased risk of thromboembolic complications (TEO). At present, it has been established that the most important cause of feasibility study is the initial, sometimes hidden, violations of the hemostasis system, predisposing to increased blood clotting and thrombosis. Their timely identification helps to personalize the use of the necessary hormonal therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.